Alba Mota

Alba Mota

Auto-generated profile, based on publicly available information

Alba Mota

Departamento de Bioquímica, Universidad Autónoma de Madrid (UAM), Instituto de Investigaciones Biomédicas 'Alberto Sols' (CSIC-UAM), IdiPAZ, Madrid, Spain

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MHMarta Hergueta-Redondo
Marta Hergueta-Redondo
DSDavid Sarrió
David Sarrió
ÁMÁngela Molina-Crespo
Ángela Molina-Crespo
DMDiego Megias
Diego Megias
AMAlba Mota
Alba Mota
GMGema Moreno-Bueno
Gema Moreno-Bueno
Gasdermin B (GSDMB) belongs to the Gasdermin protein family that comprises four members (GSDMA-D). Gasdermin B expression has been detected in some tumor types such as hepatocarcinomas, gastric and cervix cancers; and its over-expression has been related to tumor progression. At least four splicing isoforms of GSDMB have been identified, which may play differential roles in cancer. However, the implication of GSDMB in carcinogenesis and tumor progression is not well understood. Here, we uncover for the first time the functional implication of GSDMB in breast cancer. Our data shows that high levels of GSDMB expression is correlated with reduced survival and increased metastasis in breast cancer patients included in an expression dataset (>1,000 cases). We demonstrate that GSDMB is upregulated in breast carcinomas compared to normal breast tissue, being the isoform 2 (GSDMB-2) the most differentially expressed. In order to evaluate the functional role of GSDMB in breast cancer two GSDMB isoforms were studied (GSDMB-1 and GSDMB-2). The overexpression of both isoforms in the MCF7 breast carcinoma cell line promotes cell motility and invasion, while its silencing in HCC1954 breast carcinoma cells decreases the migratory and invasive phenotype. Importantly, we demonstrate that both isoforms have a differential role on the activation of Rac-1 and Cdc-42 Rho-GTPases. Moreover, our data support that GSMDB-2 induces a pro-tumorigenic and pro-metastatic behavior in mouse xenograft models as compared to GSDMB-1. Finally, we observed that although both GSDMB isoforms interact in vitro with the chaperone Hsp90, only the GSDMB-2 isoform relies on this chaperone for its stability. Taken together, our results provide for the first time evidences that GSDMB-2 induces invasion, tumor progression and metastasis in MCF7 cells and that GSDMB can be considered as a new potential prognostic marker in breast cancer.

22 July 2016 in Oncotarget
Verified
Journal Article
Open access
MHMarta Hergueta-Redondo
Marta Hergueta-Redondo
DSDavid Sarrio
David Sarrio
ÁMÁngela Molina-Crespo
Ángela Molina-Crespo
RVRocío Vicario
Rocío Vicario
CBCristina Bernadó-Morales
Cristina Bernadó-Morales
GMGema Moreno-Bueno
Gema Moreno-Bueno
Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer

1 January 2017 in Laboratory Investigation
Verified
Journal Article
Closed access
AMAlba Mota
Alba Mota
ECEva Colás
Eva Colás
PGPablo García-Sanz
Pablo García-Sanz
ICIrene Campoy
Irene Campoy
ARAlejandro Rojo-Sebastián
Alejandro Rojo-Sebastián
GMGema Moreno-Bueno
Gema Moreno-Bueno

1 August 2016 in EBioMedicine
Verified
Journal Article
Open access
KHKarin Hellner
Karin Hellner
FMFabrizio Miranda
Fabrizio Miranda
DCDonatien Fotso Chedom
Donatien Fotso Chedom
SHSandra Herrero-Gonzalez
Sandra Herrero-Gonzalez
DHDaniel M. Hayden
Daniel M. Hayden
AAAhmed Ashour Ahmed
Ahmed Ashour Ahmed
Current screening methods for ovarian cancer can only detect advanced disease. Earlier detection has proved difficult because the molecular precursors involved in the natural history of the disease are unknown. To identify early driver mutations in ovarian cancer cells, we used dense whole genome sequencing of micrometastases and microscopic residual disease collected at three time points over three years from a single patient during treatment for high-grade serous ovarian cancer (HGSOC). The functional and clinical significance of the identified mutations was examined using a combination of population-based whole genome sequencing, targeted deep sequencing, multi-center analysis of protein expression, loss of function experiments in an in-vivo reporter assay and mammalian models, and gain of function experiments in primary cultured fallopian tube epithelial (FTE) cells. We identified frequent mutations involving a 40kb distal repressor region for the key stem cell differentiation gene SOX2. In the apparently normal FTE, the region was also mutated. This was associated with a profound increase in SOX2 expression (p<2(-16)), which was not found in patients without cancer (n=108). Importantly, we show that SOX2 overexpression in FTE is nearly ubiquitous in patients with HGSOCs (n=100), and common in BRCA1-BRCA2 mutation carriers (n=71) who underwent prophylactic salpingo-oophorectomy. We propose that the finding of SOX2 overexpression in FTE could be exploited to develop biomarkers for detecting disease at a premalignant stage, which would reduce mortality from this devastating disease.

2 August 2012 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
AKAgnieszka Koziol
Agnieszka Koziol
PGPilar Gonzalo
Pilar Gonzalo
AMAlba Mota
Alba Mota
ÁPÁngela Pollán
Ángela Pollán
CLCristina Lorenzo
Cristina Lorenzo
AAAlicia G. Arroyo
Alicia G. Arroyo
The mechanism by which proteolytic events translate into biological responses is not well understood. To explore the link of pericellular proteolysis to events relevant to capillary sprouting within the inflammatory context, we aimed at the identification of the collection of substrates of the protease MT1‐MMP in endothelial tip cells induced by inflammatory stimuli. We applied quantitative proteomics to endothelial cells (ECs) derived from wild‐type and MT1‐MMP‐null mice to identify the substrate repertoire of this protease in TNF‐α‐activated ECs. Bioinformatics analysis revealed a combinatorial MT1‐MMP proteolytic program, in which combined rather than single substrate processing would determine biological decisions by activated ECs, including chemotaxis, cell motility and adhesion, and vasculature development. MT1‐MMP‐deficient ECs inefficiently processed several of these substrates (TSP1, CYR61, NID1, and SEM3C), validating the model. This novel concept of MT1‐MMP‐driven combinatorial proteolysis in angiogenesis might be extendable to proteolytic actions in other cellular contexts.—Koziol, A., Gonzalo, P., Mota, A., Pollán, Á., Lorenzo, C., Colomé, N., Montaner, D., Dopazo, J., Arribas, J., Canals, F., Arroyo, A. G. The protease MT1‐MMP drives a combinatorial proteolytic program in activated endothelial cells. FASEB J. 26, 4481–4494 (2012). www.fasebj.org

30 November 2015 in BMC Cancer
Verified
Journal Article
Open access
PDF file
AMAlba Mota
Alba Mota
JTJuan Triviño
Juan Triviño
ARAlejandro Rojo-Sebastian
Alejandro Rojo-Sebastian
ÁMÁngel Martínez-Ramírez
Ángel Martínez-Ramírez
LCLuis Chiva
Luis Chiva
GMGema Moreno-Bueno
Gema Moreno-Bueno
High grade serous ovarian cancer is characterised by high initial response to chemotherapy but poor outcome in the long term due to acquired resistance. One of the main genetic features of this disease is TP53 mutation. The majority of TP53 mutated tumors harbor missense mutations in this gene, correlated with p53 accumulation. TP53 null tumors constitute a specific subgroup characterised by nonsense, frameshift or splice-site mutations associated to complete absence of p53 expression. Different studies show that this kind of tumors may have a worse prognosis than other TP53 mutated HGSC. In this study, we sought to characterise the intra-tumor heterogeneity of a TP53 null HGSC consisting of six primary tumor samples, two intra-pelvic and four extra-pelvic recurrences using exome sequencing and comparative genome hybridisation. Significant heterogeneity was found among the different tumor samples, both at the mutational and copy number levels. Exome sequencing identified 102 variants, of which only 42 were common to all three samples; whereas 7 of the 18 copy number changes found by CGH analysis were presented in all samples. Sanger validation of 20 variants found by exome sequencing in additional regions of the primary tumor and the recurrence allowed us to establish a sequence of the tumor clonal evolution, identifying those populations that most likely gave rise to recurrences and genes potentially involved in this process, like GPNMB and TFDP1. Using functional annotation and network analysis, we identified those biological functions most significantly altered in this tumor. Remarkably, unexpected functions such as microtubule-based movement and lipid metabolism emerged as important for tumor development and progression, suggesting its potential interest as therapeutic targets. Altogether, our results shed light on the clonal evolution of the distinct tumor regions identifying the most aggressive subpopulations and at least some of the genes that may be implicated in its progression and recurrence, and highlights the importance of considering intra-tumor heterogeneity when carrying out genetic and genomic studies, especially when these are aimed to diagnostic procedures or to uncover possible therapeutic strategies.